Citadel Advisors’s Valion Bio VBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding VBIO
RMI
Citadel Advisors's VBIO Position: Q3 2026 in Review
Citadel Advisors sold out of Valion Bio (VBIO) in Q3 2026, closing a stake of 2,966 shares — an estimated $38.5K sold.
Citadel Advisors first reported a position in VBIO in Q3 2023 and held it in 3 quarters. The position peaked at $38.5K in Q2 2026. 8 funds tracked by Wall St. Rank hold VBIO as of Q3 2026.
- Citadel Advisors reported no remaining Valion Bio position as of Q3 2026 after selling out during the quarter.
- Citadel Advisors sold 2,966 Valion Bio shares in Q3 2026, an estimated $38.5K.
- Citadel Advisors first reported a position in Valion Bio in Q3 2023 and held it in 3 quarters.
- Citadel Advisors's Valion Bio position peaked at $38.5K in Q2 2026.
- 8 funds tracked by Wall St. Rank held Valion Bio as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.